1. Thematic stream: inflammatory arthritis (PP01-PP31): PP01. Autoinflammatory Synovitis in Familial Mediterranean Fever is Characterized by Numerous Neutrophils Lacking Myeloperoxidase and Lysozyme, Macrophages, Mast Cells and B Cells, Up-Regulation of Galectin-1, P65 (REL A)/NF-KB and Inos, but not COX-2
- Author
-
James Cheng-Chung Wei, Tugba Baysak, Aysegul Kucukali Turkyilmaz, Hisashi Yamanaka, Izzet Fresko, Metin Ozgen, Moots Robert, Bunyamin Kisacik, Won Park, Yoshiya Tanaka, Ibrahim Batmaz, Özer Arıcan, Aytul Cakci, Serdar Budak, Jisoo Lee, Kouichi Amano, Rezzan Günaydin, Hatice Bodur, Sema Yilmaz, Yasin Tuluce, Bonnie Vlahos, Derya Kaskari, Tastekin Ebru, Ömür Kayıkçı, Suleyman Yildirim, Chun-Huang Huang, Inita Bulina, Mehmet Tosun, Erten Surkan, Johan Rönnelid, Walter Conca, Ayşegül Koç, Akın Erdal, Vıldan Altunayoğlu Çakmak, Ayhan Dinc, Ajda Bal, Mohammed Mullazehi, Hasan Battal, Sibel Süzen, Sun-Won Park, Daina Andersone, Li-Jie Shiu, Murat Toprak, Gülsüm Emel Pamuk, Çiftdemir Mert, Hyo Jin Choi, Tuba Baykal, Hideto Kameda, Josef S. Smolen, Alif Adlan Mohd Thabit, Masao Nawata, Mehmet Karakoç, Ozcan Hiz, Gulen Hatemi, Chan Hee Lee, Murat Zinnuroglu, Halil Koyuncu, Pierre Tane, Peter Nash, Tsutomu Takeuchi, Mehmet I. Arman, Shunsuke Fukuyo, Filiz Alp, Heselynn Hussein, Zuhal Atılgan, Murat Uludağ, Aylin Rezvani, Huri Ozdogan, Halil Ozkol, Ekin Sen, Yuko Kaneko, Seung Jae Hong, Ji Young Hwang, Constance Hammond, Kılınç Serdar, Eri Satoh, Chang-Hee Suh, Altinay Goksel Karatepe, Umut Kalyoncu, Daisuke Hoshi, Albert Kamanyi, Engin Tezcan, Inta Jaunalksne, Blanche Laure Ndontsa, Hong-Shen Lee, Hui Jen Ding, Mahir Ugur, Marius Mbiantcha, Zeynep Erden, Feride Gogus, Sebahattin Yurdakul, Haner Direskeneli, Altunoglu Alpaslan, Omer Karadag, Sina Esmaeilzadeh, Ruey-Hong Wong, Andrew S Koenig, Pedro Miranda, Bruce Freundlich, Taciser Kaya, Sedat Kiraz, You-Hyun Lee, Şafak Karamehmetoğlu, Ahmet Kiziltunc, Hayato Nagasawa, Erhan Capkin, Takahiko Kurasawa, Nurettin İrem Örnek, Aysegul Jale Saraç, Karel Pavelka, De Silva Vijitha, Deniz Dulgeroglu, Necati Çakır, Emel Ozcan, Remzi Çevik, alternative medicines, Erten Serhat Fuat, Kazim Senel, Ihsan Ertenli, Macfarlane Gary, Omer Nuri Pamuk, Levent Ediz, Salim Dönmez, Tugba Yalcin, El-Metwally Ashraf, Sedat Yilmaz, Suhail Al-Salam, Kentaro Hanami, Heidi Kokkonen, Kerem Gün, Solbritt Rantapää-Dahlqvist, Usta Ufuk, Kemal Nas, Selma Yazıcı, Muammer Muslım Kose, Fatih Baygutalp, Elif Gulcu, Kazuyoshi Saito, Murat Karkucak, Tastekin Nurettin, Ronald Pedersen, Birtane Murat, and Telesphore Benoit Nguelefack
- Subjects
medicine.medical_specialty ,Ankylosing spondylitis ,business.industry ,Inflammatory arthritis ,Arthritis ,medicine.disease ,Gastroenterology ,Etanercept ,Rheumatology ,Synovitis ,Internal medicine ,Rheumatoid arthritis ,Immunology ,medicine ,Pharmacology (medical) ,Methotrexate ,Adverse effect ,business ,medicine.drug - Abstract
Background: Recent recommendations have established clinical remission ideally or low disease activity (LDA) as therapeutic targets in all patients with rheumatoid arthritis (RA). Controlled studies of biologic agents have primarily assessed treatment effects in patients with severe RA; patients with moderate disease activity, whoconstitute a larger group, have received far less attention. In Period 1 of the PRESERVE trial, the proportion of subjects with moderately active RA achieving LDA or remission were evaluated after treatment with etanercept 50mg once weekly (QW) plus methotrexate for 36 weeks.Methods: Subjects with DAS28 >3.2 and ≤5.1 despite stable doses of oral methotrexate received open-label etanercept 50mg QW plus methotrexate (screening dose permitted to be titrated up to 25 mg/wk through week 28) for 36 weeks.Results: 834 subjects received treatment and were analyzed. Subjects were mostly female (83%), Caucasian (74%), RFþ (73%), and aCCPþ (78%), with a mean age of 48 years and disease duration of 7 years. Mean baseline DAS28 was 4.4; SDAI, 19.1; ESR, 22.2 mm/hr; and CRP, 12.3 mg/L. Efficacy results from Period 1 are shown in the table. The most commonly reported adverse events (AEs) were headache (6.1%), nasopharyngitis (5.4%), and upper respiratory tract infection (4.4%). Twenty-two subjects (2.6%) discontinued due to AEs.Conclusions: Substantial proportions of subjects with moderately active RA who received etanercept 50mg QW plus methotrexate for 36 weeks achieved LDA (85%-86%), DAS28 remission (67%), or SDAI remission (25%). Therefore, these ambitious goals can be achieved realistically in a high percentage of patients with moderate disease activity.
- Published
- 2011
- Full Text
- View/download PDF